TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017

Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002).

Carey Hwang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.